12.01.17
Johnson & Johnson said sales rose 10.3% to $19.7 billion for the third quarter of 2017. Operational sales results increased 9.5%, domestic sales jumped 9.7% and international sales rose 10.9% at the company.
Worldwide consumer sales leaped 2.9% to $3.4 billion for the third quarter 2017. Domestic sales decreased 0.5% and international sales increased 5.1%.
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products—primarily Tylenol analgesic products and international smoking cessation aids as well as OGX and Neutrogena beauty products, partially offset by the negative impact of domestic baby care products, according to J&J.
The company increased its sales guidance for the full-year 2017 to a range of $76.1 billion to $76.5 billion.
Worldwide consumer sales leaped 2.9% to $3.4 billion for the third quarter 2017. Domestic sales decreased 0.5% and international sales increased 5.1%.
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products—primarily Tylenol analgesic products and international smoking cessation aids as well as OGX and Neutrogena beauty products, partially offset by the negative impact of domestic baby care products, according to J&J.
The company increased its sales guidance for the full-year 2017 to a range of $76.1 billion to $76.5 billion.